Canada Markets open in 7 hrs

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.1750-0.0100 (-5.41%)
At close: 3:49PM EDT
Full screen
Previous Close0.1850
Open0.1850
Bid0.1750 x 0
Ask0.1800 x 0
Day's Range0.1750 - 0.1900
52 Week Range0.0800 - 0.2800
Volume758,617
Avg. Volume332,950
Market Cap61.416M
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateMar. 31, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

    TORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Second Annual Undruggable Leaders Forum, a virtual event to be held on September 15-16. ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be presenting he

  • GlobeNewswire

    ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference

    TORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 23rd Annual Investment Conference being held virtually September 13-15 2021. ProMIS Executive Chairman, Eugene Williams, will provide an update

  • GlobeNewswire

    ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors

    TORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Josh Mandel-Brehm to its Board of Directors with immediate effect. “I am delighted to welcome Josh Mandel-Brehm as a member of the ProMIS Board of Directors